Drug Trial Radar · NCT07894341
A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Sep 26, 2026
Primary completion
Aug 31, 2041
Study completion Jun 30, 2042
Sponsor
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years, up to 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, single-arm extension study to evaluate the safety and efficacy of long-term administration of Inpegsomatropin Injection in participants with Idiopathic Short Stature (ISS) who have completed Phase Ⅲ clinical trials. Upon completion of the Phase Ⅲ clinical study, participants may enter the extension-phase baseline assessment period after the participant and their guardian provide informed consent, based on the willingness of the participant and guardian as well as the investigator's comprehensive assessment of the benefit-risk profile for the participant's continued participation in this study. Participants who meet all inclusion criteria and do not meet any exclusion criteria will proceed to the extension-phase treatment period to receive continued treatment with Inpegsomatropin Injection. Upon completion of the treatment period, participants will enter the final-height follow-up period, during which growth and development status, medication exposure and safety will be followed up via outpatient visits. This study aims to observe the long-term safety and efficacy of the investigational product.
Conditions
- Idiopathic Short Stature
Interventions
Inpegsomatropin InjectionDrug
Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly,treatment is continued until participants reach near-adult height.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results.Time frame: Every 13 weeks during the first year, and then every 52 weeks (up to 16 years)
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Capital Institute of Pediatrics, Beijing (SHOUER)
Beijing, China · Recruiting
Hunan Children's Hospital
Changsha, China · Recruiting
Chengdu Women's and Children's Central Hospital
Chengdu, China · Recruiting
West China Second University Hospital, Sichuan University
Chengdu, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China · Recruiting
The Third Affiliated Hospital, Sun Yat-sen University
Guangzhou, China · Recruiting
Anhui Provincial Children's Hospital
Hefei, China · Recruiting
The Second Affiliated Hospital of Anhui Medical University
Hefei, China · Recruiting
Jiaxing First Hospital
Jiaxing, China · Recruiting
Affiliated Hospital of Jining Medical University
Jining, China · Recruiting
Kunming Children's Hospital
Kunming, China · Recruiting
Gansu Provincial Maternity and Child Care Hospital
Lanzhou, China · Recruiting
Jiangxi Provincial Children's Hospital
Nanchang, China · Recruiting
Nanjing Children's Hospital
Nanjing, China · Recruiting
The Affiliated Women's and Children's Hospital of Ningbo University
Ningbo, China · Recruiting
Children's Hospital of Shanghai
Shanghai, China · Recruiting
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China · Recruiting
Shanghai Children's Medical Center
Shanghai, China · Recruiting
Children's Hospital Affiliated to Soochow University
Suzhou, China · Recruiting
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, China · Recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
Wuhan Children's Hospital
Wuhan, China · Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, China · Recruiting
Xiangyang Central Hospital
Xiangyang, China · Recruiting
Henan Children's Hospital Zhengzhou Children's Hospital
Zhengzhou, China · Recruiting
Zhuzhou Central Hospital
Zhuzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.